CONSOLIDATED STATEMENTS OF (DEFICIT) EQUITY - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Sep. 30, 2017	$ 684	$ 243,530,551	$ (236,673,155)	$ 0	$ 6,858,080
Balance (in shares) at Sep. 30, 2017	684,427
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in private placement, net of offering costs	$ 69	4,232,931	0	0	4,233,000
Common stock issued in private placement, net of offering costs (in shares)	68,375
Stock based compensation expense	$ 0	1,356,351	0	0	1,356,351
Net loss	0	0	(11,692,928)	0	(11,692,928)
Balance at Sep. 30, 2018	$ 753	249,119,833	(248,366,083)	0	$ 754,503
Balance (in shares) at Sep. 30, 2018	752,802				752,802
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in public offering, net of offering costs	$ 150	2,463,441	0	0	$ 2,463,591
Common stock issued in public offering, net of offering costs (in shares)	150,000
Common stock issued in private placement, net of offering costs	$ 39	402,342	0	0	402,381
Common stock issued in private placement, net of offering costs (in shares)	38,704
Exercise of warrants	$ 55	987,446	0	0	987,501
Exercise of warrants (in shares)	55,376
Exercise of warrants cashlessly	$ 100	(100)	0	0	0
Exercise of warrants cashlessly (in shares)	100,617
Common stock issued in secured convertible note conversion	$ 103	1,440,402	0	0	1,440,505
Common stock issued in secured convertible note conversion (in shares)	102,900
Deemed dividend - warrant repricing	$ 0	309,607	(309,607)	0
Investment in LineaRx, Inc.	0	110,849	0	2,283	113,132
Impact of adoption of new accounting pronouncements included in accumulated deficit	0	0	493,224	0	493,224
Stock based compensation expense	0	1,129,110	0	0	1,129,110
Net loss	0	0	(8,623,123)	(9,323)	(8,632,446)
Balance at Sep. 30, 2019	$ 1,200	$ 255,962,930	$ (256,805,589)	$ (7,040)	$ (848,499)
Balance (in shares) at Sep. 30, 2019	1,200,399				1,200,399